{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4
  ],
  "modelUsed": "gemini-3-flash-preview",
  "confidence": 1.0,
  "documentStructure": {
    "documentContentReferences": [
      {
        "id": "ref_1",
        "name": "Schedule of Activities Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "N/A",
        "sectionTitle": "Schedules of Activities",
        "description": "Reference to affected sections regarding C-SSRS administration"
      },
      {
        "id": "ref_2",
        "name": "Section 6 Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "6",
        "sectionTitle": "Study Procedures",
        "description": "Reference to Section 6 regarding C-SSRS administration and dosing"
      },
      {
        "id": "ref_3",
        "name": "Section 5 Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5",
        "sectionTitle": "Study Treatments",
        "description": "Reference to Section 5 regarding dosing administration and rescue treatment"
      },
      {
        "id": "ref_4",
        "name": "Section 1 Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "1",
        "sectionTitle": "Introduction",
        "description": "Reference to Section 1 regarding PK sample analysis and study design"
      },
      {
        "id": "ref_5",
        "name": "Section 2 Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "2",
        "sectionTitle": "Study Objectives and Endpoints",
        "description": "Reference to Section 2 regarding PK sample analysis and objectives"
      },
      {
        "id": "ref_6",
        "name": "Section 7 Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "7",
        "sectionTitle": "Study Assessments",
        "description": "Reference to Section 7 regarding PK sample analysis and HBV monitoring"
      },
      {
        "id": "ref_7",
        "name": "Appendix 3 Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 3",
        "sectionTitle": "Prohibited Concomitant Medications",
        "description": "Reference to washout periods for CYP2C9 and CYP2C19 inducers"
      },
      {
        "id": "ref_8",
        "name": "Section 4 Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "4",
        "sectionTitle": "Subject Eligibility",
        "description": "Reference to Section 4 regarding HBV monitoring in Taiwan and China"
      },
      {
        "id": "ref_9",
        "name": "Section 3 Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "3",
        "sectionTitle": "Study Design",
        "description": "Reference to Section 3 regarding study design and dosing interruptions"
      },
      {
        "id": "ref_10",
        "name": "Section 9 Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "9",
        "sectionTitle": "Statistical Methods and Data Analysis",
        "description": "Reference to Section 9 regarding per-protocol analysis and endpoints"
      },
      {
        "id": "ref_11",
        "name": "Section 7.8 Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "7.8",
        "sectionTitle": "Patient Reported Outcomes",
        "description": "Reference to collection of PRO data"
      },
      {
        "id": "ref_12",
        "name": "Appendix 4 Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 4",
        "sectionTitle": "N/A",
        "description": "Reference to temporary interruption of dosing and discontinuation criteria"
      }
    ],
    "commentAnnotations": [
      {
        "id": "annot_1",
        "text": "The Columbia Suicide Severity Rating Scale (C-SSRS) will be administered to all ongoing subjects at all remaining scheduled visits in Run In and Blinded treatments, and Rescue weeks 0, 8, 12, 16, and up to and including the EOT/ET and/or the EOS visit.",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Document History - Amendment 5",
        "pageNumber": 2
      },
      {
        "id": "annot_2",
        "text": "For Taiwan only: Similar to China, other countries in Asia, such as Taiwan, have a high prevalence of HBsAg negative, HBcAb positive, and HBsAb positive serology.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Document History - Amendment 4",
        "pageNumber": 3
      },
      {
        "id": "annot_3",
        "text": "These changes are in effect for China only: Subjects who are HBsAg negative, HBcAb positive, and HBsAb positive at Screening will have reflex testing for HBV DNA.",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Document History - Amendment 3",
        "pageNumber": 3
      }
    ],
    "studyDefinitionDocumentVersions": [
      {
        "id": "ver_1",
        "versionNumber": "5.0",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2019-10-28",
        "description": "Final Protocol Amendment 5 incorporating C-SSRS administration updates and administrative clarifications",
        "amendmentNumber": "Amendment 5"
      },
      {
        "id": "ver_2",
        "versionNumber": "4.0",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2018-11-27",
        "description": "Incorporation of HBV monitoring for Taiwan",
        "amendmentNumber": "Amendment 4"
      },
      {
        "id": "ver_3",
        "versionNumber": "3.0",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2018-09-12",
        "description": "Incorporation of HBV DNA reflex testing for China",
        "amendmentNumber": "Amendment 3"
      },
      {
        "id": "ver_4",
        "versionNumber": "2.0",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2018-07-23",
        "description": "Updates to background, objectives, study design, and GDPR language",
        "amendmentNumber": "Amendment 2"
      },
      {
        "id": "ver_5",
        "versionNumber": "1.0",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2018-06-20",
        "description": "Initial revisions",
        "amendmentNumber": "Amendment 1"
      }
    ],
    "summary": {
      "referenceCount": 12,
      "annotationCount": 3,
      "versionCount": 5
    }
  }
}